Q-omics provides the consensus-scored TTC34 profile across patient tissues and cancer cell-line models. TTC34 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TTC34 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, TTC34 RNA expression shows 18,515 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, THCA, and UVM as cancer lineages where TTC34 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TTC34 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TTC34 survival associations across molecular data types. TTC34 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TTC34 RNA expression–survival associations across cancer types. High TTC34 expression shows unfavorable associations in LGG, ACC and KICH, but favorable associations in BRCA, KIRP and MESO. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for TTC34 RNA expression.
This table summarizes TTC34 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TTC34. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TTC34 shows lower tumor expression in THCA, LUAD, BRCA and KICH and higher tumor expression in COAD and KIRC. The THCA box plot shows higher TTC34 RNA expression in normal versus tumor tissue (log2 FC = −1.157, t-test p < 0.001).
This table shows molecular features associated with TTC34 in patient tissues and cancer cell lines. In patient samples, TTC34 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TTC34 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and UPPER_AERODIGESTIVE_TRACT.
